Browsed by
Tag: Psoriasis

Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis

Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis

VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of psoriasis. Psoriasis is a chronic inflammatory skin disease often linked to depression and a decreased quality of life. The global psoriasis treatment market is projected to reach USD $37 billion by 2026. These results come on the heels of a successful preclinical study in atopic dermatitis earlier this year using the same drug.

In the trial, we observed significant inhibitory effects in a dose dependent manner in all concentration ranges tested. Used as a positive control, Dermavant Sciences’ psoriasis drug tapinarof also showed significant antipsoriatic activity in a preclinical trial using the same mouse model. Our drug showed comparable inhibitory effects to tapinarof over a similar range of concentrations. Derm-Biome’s compound inhibits pro-inflammatory cytokine production, it up-regulates anti-inflammatory mediators including interferons and other anti-inflammatory cytokines, and enhances expression of proteins key to maintaining an effective skin barrier. The compound also promotes skin microbiome diversity by inhibiting the growth of pathogenic bacteria, including staph and C. acnes. 

Dr. Youwen Zhou, Professor in the Department of Dermatology and Skin Science, University of British Columbia: “My group ran both the psoriasis and atopic dermatitis trials for Derm-Biome using well established mouse models that I find accurately mimic these human diseases. I have also used these mouse models for other investigational compounds and FDA approved drugs. The Derm-Biome compound blocked the development of psoriasis and atopic dermatitis in a dose dependent manner, both in terms of inflammation scores and in inhibition of the inflammatory mediators of these diseases. It is a compound with promising potential

Read the rest